LOS ANGELES, Oct. 17, 2018 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today
announced that on October 16, 2018,
the Company received notice from the NYSE American LLC ("NYSE
American" or the "Exchange") that it has determined to commence
proceedings to delist the Company's Common Stock (NYSE American:
IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS)
from the Exchange. Trading in the Company's securities on NYSE
American has been suspended.
The NYSE American determined that the Company is no longer
suitable for listing pursuant to Section 1003 of the NYSE American
Company Guide, due to the abnormally low trading price of its
Common Stock. Under the NYSE delisting procedures,
the Company has a right to a review of this determination by a
Committee of the Board of Directors of the NYSE. The Company
has determined not to seek this review. The NYSE American is
expected to apply to the Securities and Exchange Commission to
delist the Company's Common Stock and Listed Common Stock Warrants
upon completion of all applicable procedures. The Company
anticipates its Common Stock will be quoted on the OTC Markets.
Forward-Looking Statements for ImmunoCellular
Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the Company's intentions and current
expectations concerning, among other things, the NYSE American's
efforts to delist the Company's Common Stock and Listed Common
Stock Warrants from the NYSE American, the Company's intention to
deregister its Common Stock and Listed Common Stock Warrants under
the Exchange Act of 1934, as amended, and the quotation of the
Company's securities on the OTC Markets. Forward-looking statements
are not guarantees of future performance and are subject to a
number of risks and uncertainties, including the availability of
resources to continue to develop the Company's product candidates
and the uncertain timing of completion and success of clinical
trials. Additional risks and uncertainties are described under the
heading "Risk Factors" in the Company's quarterly report
on Form 10-Q for the period ended June 30, 2018
and subsequent filings with the SEC. Except as required by law, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Jane Green
(267) 457-3734 direct
(415) 652-4819 mobile
jane@jmgcomm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunocellular-announces-receipt-of-notice-of-noncompliance-with-the-nyse-american-continued-listing-standards-300732433.html
SOURCE ImmunoCellular Therapeutics, Ltd.